Key facts
- This page summarizes Steve Elms's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Dec 2024, 16:01.
Steve Elms - 23 Dec 2024 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)
- Reporting relationship
- Director
- Issuer ticker
- MRKR
- Reported as of
- 23 Dec 2024
- Net transaction value
- +$35,472
- SEC form
- 4
- Accepted by SEC
- 26 Dec 2024, 16:01:17 UTC
- Prior SEC filing
- 02 Dec 2024
- Next SEC filing
- 14 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Julio C. Esquivel, as Attorney-in-Fact for Steve Elms
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steve Elms filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 26 Dec 2024.
Change
- Previous filing in this sequence was filed on 02 Dec 2024.
- Current net transaction value: +$35,472.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRKR
transaction
Common Stock
Purchase
- Transaction value
- $35,472
- Shares
- +11,085
- Change %
- +3.5%
- Price
- $3.20
- Shares after
- 325,370
- Date
- 23 Dec 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
MRKR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,968
- Date
- 23 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F2
Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024.
Footnote F3
The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.